GlassScriptPhysician profile
Dale Voges
NPI 1629663331
$2,312.87
in general payments reported to CMS, 2019-2025
28 companies · $655 in 2025
The $655 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.20 · 2022: $484 · 2023: $677 · 2024: $400 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $351.94 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $279.08 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.55 | 2023-2025 | Jardiance, Synjardy, Ofev |
| Abbvie INC. | $150.41 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $111.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $81.78 | 2022-2024 | Trelegy Ellipta |
| Mylan Specialty L.P. | $74.03 | 2022-2023 | Yupelri |
| Amgen INC. | $67.89 | 2023-2025 | Otezla, Repatha, Evenity |
| Tandem Diabetes Care, INC. | $51.53 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $47.88 | 2025 | Tymlos |
| Inari Medical, INC. | $47.53 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $39.99 | 2024-2025 | |
| Corcept Therapeutics | $39.19 | 2024-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $37.08 | 2024 | Unithroid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $35.74 | 2025 | Xyosted |
| Insulet Corporation | $33.05 | 2024-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $32.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.73 | 2022 | |
| Dynavax Technologies Corporation | $20.55 | 2023 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $20.34 | 2023 | |
| Esperion Therapeutics, INC. | $17.25 | 2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $16.35 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.97 | 2023 | Quviviq |
| Pfizer INC. | $14.88 | 2024 | |
| Currax Pharmaceuticals LLC | $14.02 | 2023 | Onzetra Xsail, Contrave |
| Verity Pharmaceuticals INC. | $13.84 | 2024 | Tlando |
| Medtronic, INC. | $13.64 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Voges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.